Analytical Data
-
Gene name
BZLF2
- Application
-
Species
Epstein-Barr virus
-
Source
E. coli
-
Tag
N- His & C- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0C6Z5
-
Expression Region
34-223aa
-
Molecular Weight
28.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BZLF2, a protein encoded by the Epstein-Barr virus (EBV), plays a crucial role in the virus's lytic cycle and is involved in the transition from latency to active replication. As a transcription factor, BZLF2 binds to specific DNA elements, activating the expression of immediate-early genes necessary for the viral life cycle. EBV, a member of the herpesvirus family, is associated with various diseases, including infectious mononucleosis and certain types of cancer, such as Burkitt's lymphoma and nasopharyngeal carcinoma. Understanding BZLF2's structure, function, and interactions with host cellular machinery is vital for elucidating EBV pathogenesis and developing potential therapeutic strategies. Research on BZLF2 has involved recombinant protein production, allowing scientists to study its biochemical properties, analyze its role in viral gene regulation, and explore its potential as a target for antiviral therapies. Moreover, BZLF2's ability to modulate host immune responses highlights its importance in viral persistence and the complexity of EBV's relationship with human biology. Thus, ongoing studies aim to unravel the multifaceted roles of BZLF2 in EBV pathophysiology and its implications for disease management.
